Abbott Laboratories (ABT) · Oct 21, 2026 · Disposition
$8.5B Nutrition separation — Approximately $8.5B annual sales; completion targeted by end-2027
Abbott’s planned Nutrition separation creates a new $8.5B company while the remaining business concentrates on devices, diagnostics and medicines.
Abbott enters this move as a diversified healthcare company whose recent growth has been led by Medical Devices and Established Pharmaceuticals, while Nutrition has been a slower-growth segment.
This is a genuine portfolio reset, not a financing event. Abbott plans to distribute shares of a standalone Nutrition company directly to existing shareholders, leaving them with ownership of both businesses rather than raising cash or buying another asset. 〔0〕 The new company would have approximately $8.5 billion in annual sales, while the remaining Abbott would have approximately $42 billion in sales.
The strategic logic is clear: isolate a branded consumer-health business and sharpen Abbott around higher-growth healthcare platforms. Nutrition gets its own capital allocation and operating focus across infant, pediatric, medical and adult nutrition; Abbott keeps medical devices, biowearables, diagnostics and established medicines. That advances Abbott’s stated growth strategy, but the filing does not yet prove that separation will improve either company’s economics.
The event is strategically meaningful but financially incomplete. Abbott gives no standalone margins, cash flow, debt structure, stranded-cost estimate or detailed dividend allocation for the future Nutrition company. It also flags transaction charges that have not yet been quantified. 〔1〕 The intended tax-free treatment and promise that the combined dividend will equal Abbott’s dividend at separation soften the disruption, but they do not resolve the missing economics.
Execution is a long way off. Completion is targeted for the end of 2027 and remains subject to regulatory approvals, a Form 10 registration statement and final board approval. 〔2〕 The filing says 2026 guidance and the 2027 outlook planned for January are unchanged, so this is a structural change to the story rather than an immediate earnings reset.
Bottom line: Abbott is making its portfolio easier to understand by separating a sizable but distinct Nutrition business from its faster-growing healthcare platforms. The move matters strategically, but the market still lacks the standalone financial details needed to judge whether the separation creates value or merely adds execution complexity.
2027 guidance update in January
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!